• 1
    Krupp LB, Lipton RB, Swerdlow ML, Leeds NE, Llena J. Progressive multifocal leukoencephalopathy: Clinical and radiographic features. Ann Neurol 1985; 17: 344349.
  • 2
    Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A. Progressive multifocal leukoencephalopathy: A review of the neuroimaging features and differential diagnosis. Euro J Neurol 2012; 19: 10601069.
  • 3
    Singh N, Bonham A, Fukui M. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. Transplantation 2000; 69: 467472.
  • 4
    Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1: 12571260. Epub 1971/06/19. eng.
  • 5
    Dorries K. Progressive multifocal leucoencephalopathy: Analysis of JC virus DNA from brain and kidney tissue. Virus Res 1984; 1: 2538. Epub 1984/01/01. eng.
  • 6
    Yogo Y, Kitamura T, Sugimoto C, et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol 1990; 64: 31393143. Epub 1990/06/01. eng.
  • 7
    Jing D, Oelschlaegel U, Ordemann R, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010; 45: 14891496. Epub 2010/01/26. eng.
  • 8
    Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66: 255258. Epub 2009/02/11. eng.
  • 9
    Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186(Suppl 2): S180S186. Epub 2002/11/09. eng.
  • 10
    Kedar S, Berger JR. The changing landscape of progressive multifocal leukoencephalopathy. Curr Infect Dis Rep 2011; 13: 380386. Epub 2011/05/24. eng.
  • 11
    Taguchi F, Kajioka J, Miyamura T. Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 1982; 26: 10571064. Epub 1982/01/01. eng.
  • 12
    Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71: 115123. Epub 2003/07/15. eng.
  • 13
    Astrom KE, Mancall EL, Richardson EP, Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81: 93111. Epub 1958/03/01. eng.
  • 14
    Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75: 13261332. Epub 2010/10/13. eng.
  • 15
    Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987; 107: 7887.
  • 16
    Lang W, Miklossy J, Deruaz JP, et al. Neuropathology of the acquired immune deficiency syndrome (AIDS): A report of 135 consecutive autopsy cases from Switzerland. Acta Neuropathol 1989; 77: 379390.
  • 17
    Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4: 5968. Epub 1998/04/08. eng.
  • 18
    Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48: 14591466. Epub 2009/04/08. eng.
  • 19
    Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999; 52: 623625. Epub 1999/02/20. eng.
  • 20
    Major EO. History and current concepts in the pathogenesis of PML. Cleveland Clin J Med 2011; 78(Suppl 2): S3S7. Epub 2011/12/14. eng.
  • 21
    Rudick RA. Multiple sclerosis, natalizumab, and PML: Helping patients decide. Cleveland Clin J Med 2011; 78(Suppl 2): S18S23. Epub 2011/12/14. eng.
  • 22
    Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18: 143152. Epub 2012/02/09. eng.
  • 23
    Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology 2008; 71: 357364. Epub 2008/07/30. eng.
  • 24
    Schon MP. Efalizumab in the treatment of psoriasis: Mode of action, clinical indications, efficacy, and safety. Clin Dermatol 2008; 26: 509514. Epub 2008/08/30. eng.
  • 25
    Molloy ES. PML and rheumatology: The contribution of disease and drugs. Cleveland Clin J Med 2011; 78(Suppl 2): S28S32. Epub 2011/12/14. eng.
  • 26
    Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 21882195. Epub 1997/10/06. eng.
  • 27
    Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62: 258264. Epub 2005/02/16. eng.
  • 28
    Reinsmoen NL, Lai CH, Vo A, Jordan SC. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med 2012; 13: 267273. Epub 2012/05/01. eng.
  • 29
    Montgomery RA, Cozzi E, West LJ, Warren DS. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol 2011; 23: 224234. Epub 2011/10/01. eng.
  • 30
    Blume OR, Yost SE, Kaplan B. Antibody-mediated rejection: Pathogenesis, prevention, treatment, and outcomes. J Transplant 2012; 2012: 201754. Epub 2012/05/01. eng.
  • 31
    Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 48344840. Epub 2009/03/07. eng.
  • 32
    Flomenbaum MA, Jarcho JA, Schoen FJ. Progressive multifocal leukoencephalopathy fifty-seven months after heart transplantation. J Heart Lung Transplant 1991; 10: 888893. Epub 1991/11/01. eng.
  • 33
    Verhelst X, Vanhooren G, Vanopdenbosch L, et al. Progressive multifocal leukoencephalopathy in liver transplant recipients: A case report and review of the literature. Transpl Int 2011; 24: e30e34. Epub 2010/12/08. eng.
  • 34
    Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86: 14741478. Epub 2008/11/27. eng.
  • 35
    Pelosini M, Focosi D, Rita F, et al. Progressive multifocal leukoencephalopathy: Report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 2008; 87: 405412. Epub 2007/12/08. eng.
  • 36
    Pavlovic AM, Bonaci-Nikolic B, Kozic D, et al. Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus 2012; 21: 100102. Epub 2011/10/07. eng.
  • 37
    Aksamit AJ, Jr., de Groen PC. Cyclosporine-related leukoencephalopathy and PML in a liver transplant recipient. Transplantation 1995; 60: 874876. Epub 1995/10/27. eng.
  • 38
    Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70: 305322. Epub 2011/08/09. eng.
  • 39
    Baek CH, Yang WS, Park KS, Han DJ, Park JB, Park SK. Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation. Nephron Extra 2012; 2: 6675. Epub 2012/05/24. eng.
  • 40
    Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402409. Epub 2009/02/04. eng.
  • 41
    Calabrese L. A rational approach to PML for the clinician. Cleveland Clin J Med 2011; 78(Suppl 2): S38S41. Epub 2011/12/14. eng.
  • 42
    Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338: 13451351. Epub 1998/05/08. eng.
  • 43
    Garrote FJ, Molina JA, Lacambra C, Mollejo M, Madero S, del Ser T. [The inefficacy of zidovudine (AZT) in progressive multifocal leukoencephalopathy (PML) associated with the acquired immunodeficiency syndrome (AIDS)]. Revista Clinica Espanola 1990; 187: 404407. Epub 1990/11/01. Ineficacia de la zidovudina (AZT) en la leucoencefalopatia multifocal progresiva (LMP) asociada al sindrome de inmunodeficiencia adquirida (SIDA). spa.
  • 44
    Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Aids 2002; 16: 17911797. Epub 2002/09/10. eng.
  • 45
    Stuve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: Possible interventions. Arch Neurol 2007; 64: 169176. Epub 2007/02/14. eng.
  • 46
    Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrobial Agents Chemother 2009; 53: 18401849. Epub 2009/03/05. eng.
  • 47
    Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306: 13801383. Epub 2004/11/20. eng.
  • 48
    Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007; 196: 709711. Epub 2007/08/04. eng.
  • 49
    Balduzzi A, Lucchini G, Hirsch HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 2011; 46: 987992.